How to use Hulio®

Hulio® is an approved biosimilar of adalimumab. As such, it has undergone a rigorous review process to achieve European Medicines Agency (EMA) approval1; it offers highly similar quality, safety and efficacy compared with its reference product, including its disease-modifying efficacy and its safety profile among the various indications. Hulio® helps in improving the current symptoms and could aid in preventing future complications and the need for surgery in certain conditions.

Indications for Hulio®

Please refer to SmPC for full prescribing information.

Hulio® is indicated in several therapeutic areas such as:2


  • Rheumatoid arthritis
  • Axial spondyloarthritis
  • Psoriatic arthritis
  • Psoriasis
  • Hidradenitis suppurativa (HS)
  • Crohn’s disease
  • Ulcerative colitis
  • Uveitis


  • Juvenile idiopathic arthritis
  • Paediatric plaque psoriasis
  • Adolescent hidradenitis suppurativa
  • Paediatric Crohn’s disease
  • Paediatric uveitis

Hulio® is indicated as second-line therapy in the conditions listed in the above table, with some exceptions in cases of active, severe disease, or where first-line therapy is not tolerated or is contraindicated. For details of Hulio® use in specific indications, please refer to the Summary of Product Characteristics.2

Benefits of Hulio®

Hulio® may deliver increased affordability compared with the originator adalimumab while still offering comparable safety, efficacy and tolerability.1 Long-term use of Hulio® may help generate significant savings for healthcare systems, which can be invested in better screening and diagnosis as well as better patient education and research.

Hulio® Administration

Hulio® is available in three presentations, including a pre-filled injection pen designed to be easy to use, for patient convenience.2

Hulio® (40mg/0.8ml) is administered via subcutaneous injection usually every other week. Hulio® is available in three presentations:

  • Pre-filled syringe (PFS)
  • Pre-filled autoinjection pen
  • Vial

The syringe and the autoinjection pen are made of durable plastic rather than glass, preventing accidental breakage and wastage of medicine. Both are also latex-free and come with narrow 29 Gauge needles for patient comfort.

Restricted access

The website you are trying to access is designed for healthcare professionals only - the content is not designed for the general public.

Are you a healthcare professional based in UK or Ireland?


Report side effects

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare providers are asked to report any suspected adverse reactions. Reporting forms and information can be found at In order to support effective tracking and traceability of biologics including biosimilars, it is recommended that the brand name and batch number are recorded and used when reporting adverse events.

You are now leaving the Hulio® uk website